Peripheral Neuropathies
Neuropathies associated with cytomegalovirus infection
Nov. 16, 2024
Worddefinition
At vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores et quas.
Polyneuropathy associated with antisulfatide antibodies …
- Updated 12.10.2023
- Released 05.15.2000
- Expires For CME 12.10.2026
Polyneuropathy associated with antisulfatide antibodies
Introduction
Overview
Antisulfatide neuropathy is an immune-mediated neuropathic disorder. It presents most commonly as an axonal sensory predominant polyneuropathy. However, demyelination may be seen in some cases. GALOP syndrome, a variant of antisulfatide neuropathy, is a disabling gait disorder in the elderly. Patients typically have gait ataxia and a distal sensory predominant polyneuropathy. This neuropathy is mostly demyelinating. Clinical testing for antisulfatide and anti-GALOP antibodies is useful in slowly progressive sensory or sensorimotor neuropathies affecting patients older than 50 years of age. Treatment for both involves neuropathic pain management and immunosuppression in the presence of demyelination.
Historical note and terminology
Antibodies against sulfatide, the major acidic glycosphingolipid in myelin, have been reported in various systemic and neurologic disorders. These antibodies have been found in disorders such as idiopathic thrombocytopenic purpura (50), autoimmune chronic active hepatitis (47), HIV (40; 26), multiple sclerosis (44), Guillain-Barré syndrome (14; 18; 49), and chronic inflammatory demyelinating polyradiculoneuropathy (38; 31). Most studies have shown an association between highly elevated titers of antisulfatide antibodies and peripheral neuropathy (33; 22; 46; 12; 06). In the first report describing antibodies to sulfatide in neuropathy, high titers were found in patients with chronic axonal, predominantly sensory neuropathy (38). Other reports followed, but patients did not appear to constitute a single clinical syndrome, and some patients had demyelination, sometimes in association with antibodies against other myelin antigens (17; 13; 34).
Pestronk and colleagues identified extremely high titers of IgM binding to a CNS myelin antigen that co-purified with myelin-associated glycoprotein in patients with gait ataxia and sensorimotor polyneuropathy. This clinical syndrome was termed the GALOP syndrome (gait disorder, autoantibody to a neural antigen, late-age onset, and polyneuropathy of mild to moderate severity) (37). The anti-CNS myelin antigen antibody was also found to cross-react with both sulfatide and myelin-associated glycoprotein. Pestronk’s studies suggested that titers greater than 1:10,000, with no cross-reactivity to GM1 ganglioside, have specificity for this syndrome. However, since that report, GALOP syndrome is now considered a variant of the antisulfatide syndrome, as the initially unknown antigen that co-purified with myelin-associated glycoprotein was subsequently determined to be sulfatide (08; 21). Meehan and colleagues created new and further refined antisulfatide antibodies that show additional reactivity; further study is needed to assess the utility (30).
Clinical manifestations
Presentation and course
Patients with antisulfatide antibodies usually present with an insidious onset, slowly progressive, distal, and symmetrical sensory or sensorimotor neuropathy, affecting the legs and arms. Sensory disturbances may involve all modalities (or predominantly the small fibers) and are usually found in a stocking and glove distribution. Muscle weakness is usually mild and affects the distal muscles or is absent (33; 25; 48; 09). A few reported patients with elevated antisulfatide antibodies had Guillain-Barré syndrome or chronic inflammatory demyelinating polyradiculoneuropathy. Some patients with IgM anti-sulfatide antibodies and accompanying IgM paraproteinemia may have an ataxic gait disorder or tremor. The presence of high titers (greater than 1:4000) of IgM antisulfatide antibodies has an 80% to 90% specificity for a sensory rather than motor neuropathy syndrome (21). In a study of 23 patients with significantly elevated antisulfatide antibodies (greater than 1:25,600) and polyneuropathy, eight patients had predominantly small-fiber neuropathy; five had mixed small- and large-fiber axonal sensory neuropathy; seven had sensorimotor axonal neuropathy; and three had chronic inflammatory demyelinating polyradiculoneuropathy. Pain was a prominent symptom in 10 patients (06). In a series of nine neuropathy patients with high antisulfatide titers, one patient had an asymmetric predominantly motor neuropathy (09). Some have questioned the diagnostic utility of this test. Giannotta and colleagues reviewed 39 cases with high sulfatide antibodies and neuropathy (15). Thirty-three (85%) had coincident myelin-associated glycoprotein antibodies (MAG), and the authors concluded that the sulfatide added questionable value. However, there were six others with elevated sulfatide titers and various forms of neuropathy, including one with very high sulfatide titer, IgM gammopathy, demyelinating neuropathy, and negative anti-MAG.
Similarly, Campagnolo and colleagues reported 23 patients with chronic, distal, symmetric, slowly progressive polyneuropathy and predominant sensory impairment; most had underlying hematological disorders (04). Most patients had IgM monoclonal gammopathy of undetermined significance, four had Waldenstrom, one had non-Hodgkin lymphoma, and two had no underlying disease. Of this group, 15 had high MAG antibody titers, four had isolated high antisulfatide titers, and four had high titers to both antibodies. Response to rituximab did not appear to correlate with the antibody pattern.
GALOP syndrome is a progressive disabling gait disorder in the elderly (36). In a study of nine patients, Pestronk and colleagues reported gait ataxia and a distal sensory-predominant sensorimotor polyneuropathy. All sensory modalities may be impaired. Weakness is mild and mainly involves distal leg musculature (37).
Distal acquired demyelinating symmetric neuropathy is an overlapping entity linked to MAG antibodies; distinction must be made with IgM monoclonal versus no monoclonal protein patients. Some studies suggest that distal acquired demyelinating symmetric patients with more axonal form have a higher frequency of antisulfatide and anti-peripheral nerve myelin reactivity and a worse long-term prognosis (28).
Sulfatide measures, mainly in urine, are an important marker of metachromatic leukodystrophy. Neuropathy is a common manifestation. Dali and colleagues studied 13 children in Denmark with metachromatic leukodystrophy, 11 of which had evidence of neuropathy (07). Sural nerve and CSF sulfatide levels were studied. Nerve levels correlated with peripheral but CSF levels did not correlate with central disease severity. Other studies found no correlation between sulfatide levels and neuropathy, implicating other possible factors (02).
Antisulfatide antibodies are reported positive in some acute onset inflammatory neuropathy cases, including Miller Fisher syndrome, a pharyngeal-sensory-ataxic variant, and Miller Fisher/Guillain Barre overlap syndromes (23; 52). The findings are typically coincident with various ganglioside antibodies.
Vignette: a case of multiple antibodies and inflammatory manifestations. A 57-year-old woman had neuromyelitis optica, undifferentiated connective tissue disease, and primarily axonal sensorimotor peripheral neuropathy. The combined pattern was associated with aquaporin IgG, various ganglioside antibodies, and antisulfatide IgG antibodies in serum and cerebrospinal fluid (24). After methylprednisolone, IVIg, plasma exchange, and rituximab treatment, the patient clinically improved and showed improved nerve conduction motor and sensory amplitude responses.
Prognosis and complications
The neuropathy associated with antisulfatide antibodies is usually slowly progressive. Pain can be a disabling symptom (48; 06). If an IgM monoclonal gammopathy is present, then Waldenstrom macroglobulinemia or chronic lymphocytic leukemia should be considered; however, most of the monoclonal gammopathies are classified as monoclonal gammopathy of uncertain significance.
Biological basis
Etiology and pathogenesis
The cause for the development of antisulfatide antibodies and their role in the pathogenesis of neuropathy are unknown.
The role of antisulfatide antibodies in the pathogenesis of neuropathy is not yet understood. Sulfatide is mainly located in the noncompact myelin of Schwann cells but can also be found in the node and paranode (43). It seems unlikely that these antibodies are simply a secondary response to axonal damage; sulfatide is a major component of myelin. Patients with widespread axonal degeneration do not generally have high titers of these antibodies. The specificity of the antibody reactivity and the occurrence of monoclonal antibodies in many patients suggest that humoral processes play a role in the pathogenesis. Mice deficient in sulfatide by knockout of cerebroside sulfotransferase enzyme develop severe neurologic abnormalities and disruption of both central and peripheral myelin, especially in paranodal regions; the mice have slow sciatic nerve conduction velocity (16).
Antisulfatide antibodies have been reported in various neurologic disorders; however, significantly elevated titers (greater than 1:12,800) were closely associated with neuropathy (42). A 1:4,000 titer for IgM antisulfatide antibodies was found to be the threshold titer for autoimmune peripheral neuropathy (19). These antibodies have been reported to bind to the surface of dorsal root ganglia neurons and peripheral nerve myelin and axons, where they might exert their effect (42; 27; 39). The binding pattern has been found to correlate with the type of neuropathy (27). It seems that antibodies against sulfatide, which is expressed in myelin and axonal membranes, bind to various antigenic epitopes, producing different types of neuropathy. Axonal, demyelinating, or mixed neuropathies have all been described with antisulfatide antibodies. However, axonal predominantly sensory neuropathy is most common. In one study of patients with antisulfatide antibodies and demyelinating neuropathy, deposits of IgM and complement were seen on myelin sheaths in peripheral nerve biopsies; in another study, passive transfer of antisulfatide antibodies was reported to induce demyelination in experimental rabbits (32; 12). However, similar findings have not been reported in nerves or sera from patients with axonal neuropathies. Sera from patients with antisulfatide antibodies can cross-react with or contain antibodies to myelin-associated glycoprotein or possibly unidentified nerve antigens (38; 17). In a series of 25 patients with antisulfatide antibody titers greater than 1:25,600, two patients with axonal neuropathy had pathological findings of primary demyelination in addition to axonal degeneration, suggesting that both processes can occur in the same nerves. However, neither had detectable deposits of IgM or complement proteins (06).
Antisulfatide antibodies (IgM and IgG) show increased titers in some rheumatological conditions, including systemic lupus erythematosus, antineutrophil cytoplasmic antibody-related small vessel vasculitis, mixed cryoglobulinemia, and Sjögren syndrome; these increases may be nondiagnostic or associated with neuropathy (01).
Monoclonal proteins are detected in some patients. Dabby and colleagues found a monoclonal gammopathy in 30% of patients (06). Interestingly, monoclonal antibodies were detected in patients with axonal sensory, sensorimotor, and demyelinating neuropathies but not in patients with small-fiber neuropathy. Total IgM was elevated in one half of the patients. In another published study of patients with antisulfatide antibodies, monoclonal gammopathy was closely associated with demyelination rather than axonal degeneration (25). Other small series also reported demyelinating neuropathy with antisulfatide antibodies and monoclonal gammopathy (05; 41). Eurelings and colleagues analyzed whether the presence of antisulfatide antibodies influences the outcome of polyneuropathy associated with IgM monoclonal gammopathy (10). This study involved 65 patients in whom known causes of neuropathy were excluded. Although antisulfatide titers were elevated in 25 patients, the antibodies did not impact the clinical course, leading the authors to conclude that antisulfatide activity in IgM paraprotein-associated neuropathies does not have prognostic value. Farhad and colleagues analyzed a large series of patients diagnosed with idiopathic neuropathy and assessed for overlooked underlying causes (11). One case out of 284 (0.3%) was found to have associated high antisulfatide titers. Another study of 87 patients with monoclonal gammopathy of undetermined significance and neuropathy found a heterogeneous group with increased sulfatide titers, but affected cases tended to be younger (29).
Klehmet and colleagues assayed ganglioside and sulfatide reactivity in inflammatory neuropathy patients, including typical CIDP and known variants (61), other neuropathy (15) and other non-neuropathy immune conditions (54), and healthy controls (54) (20). They found at least one positive assay in 28% of inflammatory neuropathy patients compared to 5% of other neuropathy and 7% in multiple sclerosis patients and healthy controls. GM1 and GD1b were most prevalent. Patients that demonstrated antisulfatide were younger and demonstrated more typical CIDP and MMN phenotypes rather than multifocal or other variants. All except one positive antisulfatide patient in this cohort also were MAG positive. Some patients in the study were receiving intravenous immunoglobulin. The study drew the study sample on the first day of the infusion cycle before the infusion.
Boso and colleagues screened 229 patients by enzyme-linked immunosorbent assay (ELISA) testing for IgM sulfatide, galactocerebroside, and a combination of the two to determine if the combined assay increased sensitivity or specificity (03). They included 73 patients with IgM paraproteinemic neuropathy, mostly anti-MAG, and 156 patients with other neuropathy forms. Controls included IgM MGUS patients without neuropathy and 28 healthy controls. They found isolated antibodies to galactocerebroside in two patients with CIDP and in one patient with anti-MAG antibody neuropathy. The combined assay Sulf/GalC, however, was positive in half of the patients with paraprotein neuropathy and few others. When a strict abnormal cutoff was employed, only the patients with IgM paraproteinemic neuropathy had an abnormal combined test. The Sulf/GalC assay increased by 24 the number of positive results in that group; in the other groups, none had more than a weak positive result.
Epidemiology
Early studies detected antisulfatide antibodies in approximately one quarter of patients with predominantly sensory polyneuropathy that otherwise would have been classified as idiopathic (38; 33). However, later studies did not duplicate such a high frequency of antisulfatide activity in this common patient population, suggesting that no more than 1% to 2% of patients with chronic unclassified sensory or sensorimotor polyneuropathies had antisulfatide antibodies (51). The gender ratio for antisulfatide-associated neuropathies remains unclear. Dabby has reported a male-to-female ratio of 1:1.3 (06). In Erb’s series, the male-to-female ratio was 7:4 (09).
Differential diagnosis
Antisulfatide-associated neuropathy shares common features with other types of chronic neuropathies. Diabetic polyneuropathy, which is typically slowly progressive, predominantly sensory, and often painful, may resemble antisulfatide neuropathy. In rare cases, patients with diabetes and neuropathy have been reported to have antisulfatide antibodies, but measured titers were low (46). Toxic or drug-induced polyneuropathies can be distinguished from antisulfatide neuropathy by a careful medical history and improvement or stabilization after withdrawal of the offending agent. Neuropathies associated with vitamin deficiencies or metabolic disorders such as renal, hepatic, or thyroid dysfunction can be reliably diagnosed with laboratory testing.
Other immune-associated neuropathies can closely resemble antisulfatide neuropathy. Antimyelin-associated glycoprotein neuropathy is characterized by markedly slow nerve conduction velocities, prolonged distal latencies, and an IgM monoclonal gammopathy in most patients. Chronic inflammatory demyelinating neuropathy usually involves both motor and sensory nerves and commonly presents with distal and proximal weakness. CSF protein is characteristically high in chronic inflammatory demyelinating polyradiculoneuropathy, and electrodiagnostic studies show a demyelinating pattern. Paraneoplastic neuropathies can be secondary to solid tumors such as small-cell lung carcinoma. Identifying the primary tumor or detection of humoral factors such as anti-Hu antibodies leads to the correct diagnosis.
A study of autoantibodies in patients with active celiac disease found low levels of various IgG and IgM ganglioside antibodies. Sulfatide IgG (36%) and IgA (19%) were found. On a strict gluten-free diet, the IgG antibodies resolved, whereas IgA persisted in two cases, although a correlation with neurologic symptoms was not clearly established (45). This link also reinforces the utility of screening neuropathy patients for celiac disease.
Diagnostic workup
Nerve conduction studies usually show features of axonal sensory or sensorimotor neuropathy (33; 48). In some patients, there is a predominantly demyelinating neuropathy with slow conduction velocities and dispersed potentials (32; 25; 31; 05; 41). In patients with predominantly small-fiber neuropathy, conduction studies may be normal. In those patients, quantitative sensory testing may show selective small-fiber involvement (38; 42; 06).
The neuropathy associated with the GALOP syndrome appears to be heterogeneous. Some features suggesting demyelination are found in 80% of patients. Prolonged distal latencies and slow conduction velocities are commonly seen, although conduction block is not evident.
Information about the pathological changes in the nerves of patients with neuropathy and elevated antisulfatide antibodies is limited. Biopsy studies can reveal normal histology, axonal degeneration, or demyelination (42; 33; 27; 12). In one series, two patients with axonal neuropathy had pathological findings of primary demyelination (ie, thinly myelinated fibers and small onion bulbs). These findings were superimposed over evidence of axonal degeneration (06).
Antisulfatide antibodies are most reliably detected by enzyme-linked immunosorbent assay, using sulfatide as the antigen. Several factors increase the likelihood of a positive test, such as age greater than 50 years, disability from neuropathic symptoms, gait disorder, tremor, electrophysiologic evidence of demyelination, and IgM monoclonal gammopathy (35). Detection of the monoclonal protein, which occurs in a substantial number of patients, is best done by serum protein immunoelectrophoresis or immunofixation electrophoresis. If a monoclonal protein is present, a bone marrow biopsy is indicated to rule out Waldenstrom macroglobulinemia.
Management
Supportive measures are discussed in Peripheral neuropathies: supportive measures and rehabilitation.
There is little information to guide the management of neuropathies associated with antisulfatide antibodies or the GALOP syndrome. Patients with demyelinating features are treated similarly to those with chronic inflammatory demyelinating polyradiculopathy. Pain management is often the focus for patients with painful, small-fiber presentations; they may respond to antidepressants or anticonvulsants used for other causes of neuropathic pain. Patients with monoclonal gammopathies should be evaluated for the presence of a B-cell lymphoproliferative disorder.
Pestronk and colleagues successfully treated a few patients with GALOP syndrome using immunomodulators such as intravenous gammaglobulin, plasmapheresis, and cyclophosphamide (36).
References
- 01
- Alpa M, Ferrero B, Cavallo R, et al. Anti-GM1 and anti-sulfatide antibodies in patients with systemic lupus erythematosus, Sjögren's syndrome, mixed cryoglobulinemia and idiopathic systemic vasculitis. Clin Exp Rheumatol 2007;25(4):556-62. PMID 17888211
- 02
- Beerepoot S, Nierkens S, Boelens JJ, Lindemans C, Bugiani M, Wolf NI. Peripheral neuropathy in metachromatic leukodystrophy: current status and future perspective. Orphanet J Rare Dis 2019;14(1):240. PMID 31684987
- 03
- Boso F, Ruggero S, Giannotta C, et al. Anti-sulfatide/galactocerebroside antibodies in immunoglobulin M paraproteinemic neuropathies. Eur J Neurol 2017;24(11):1334-40. PMID 28782863
- 04
- Campagnolo M, Ferrari S, Dalla Torre C, et al. Polyneuropathy with anti-sulfatide and anti-MAG antibodies: clinical, neurophysiological, pathological features and response to treatment. J Neuroimmunol 2015;281:1-4. PMID 25867460
- 05
- Carpo M, Meucci N, Allaria S, et al. Anti-sulfatide antibodies in peripheral neuropathy. J Neurol Sci 2000;176:144-50. PMID 10930598
- 06
- Dabby R, Weimer LH, Hays AP, Olarte M, Latov N. Anti-sulfatide antibodies in neuropathy: clinical and electrophysiologic correlates. Neurology 2000;54:1448-52. PMID 10751255
- 07
- Dali CI, Barton NW, Farah MH, et al. Sulfatide levels correlate with severity of neuropathy in metachromatic leukodystrophy. Ann Clin Transl Neurol 2015;2(5):518-33. PMID 26000324
- 08
- Donofrio PD. Immunotherapy of idiopathic inflammatory neuropathies. Muscle Nerve 2003;28(3):273-92. PMID 12929187
- 09
- Erb S, Ferracin F, Fuhr P, et al. Polyneuropathy attributes: a comparison between patients with anti-MAG and anti-sulfatide antibodies. J Neurol 2000;247:767-72. PMID 11127531
- 10
- Eurelings M, Moons KG, Notermans NC, et al. Neuropathy and IgM M-proteins. Prognostic value of antibodies to MAG, SGPG, and sulfatide. Neurology 2001;56:228-33. PMID 11160960
- 11
- Farhad K, Traub R, Ruzhansky KM, Brannagan TH 3rd. Causes of neuropathy in patients referred as "idiopathic neuropathy". Muscle Nerve 2016;53(6):856-61. PMID 26561790
- 12
- Ferrari S, Morbin M, Nobile-Orazio E, et al. Antisulfatide polyneuropathy: antibody- mediated complement attack on peripheral myelin. Acta Neuropathol 1998;96(6):569-74. PMID 9845286
- 13
- Fredman P, Lycke J, Andersen O, Vrethem M, Ernerudh J, Svennerholm L. Peripheral neuropathy associated with monoclonal IgM antibody to glycolipids with a terminal glucuronyl-3-sulfate epitope. J Neurol 1993;240:381-7. PMID 7687665
- 14
- Fredman P, Vedeler CA, Nyland H, Aarli JA, Svennerholm L. Antibodies in sera from patients with inflammatory demyelinating polyradiculoneuropathy react with ganglioside LM1 and sulphatide of peripheral nerve myelin. J Neurol 1991;238:75-9. PMID 1856740
- 15
- Giannotta C, Di Pietro D, Gallia F, Nobile-Orazio E. Anti-sulfatide IgM antibodies in peripheral neuropathy: to test or not to test? Eur J Neurol 2015;22(5):879-82. PMID 25597226
- 16
- Hayashi A, Kaneko N, Tomihira C, Baba H. Sulfatide decrease in myelin influences formation of the paranodal axo-glial junction and conduction velocity in the sciatic nerve. Glia 2013;61(4):466-74. PMID 23322453
- 17
- Ilyas AA, Cook SD, Dalakas MC, Mithen FA. Anti-MAG IgM paraproteins from some patients with polyneuropathy associated with IgM paraproteinemia also react with sulfatide. J Neuroimmunol 1992;37:85-92. PMID 1372333
- 18
- Ilyas AA, Mithen FA, Dalakas MC, et al. Antibodies to sulfated glycolipids in Guillain-Barre syndrome. J Neurol Sci 1991;105:108-17. PMID 1795163
- 19
- Isoardo G, Ferrero B, Barbero P, et al. Anti-GM1 and anti-sulfatide antibodies in polyneuropathies. Acta Neurol Scand 2001;103:180-7. PMID 11240566
- 20
- Klehmet J, Märschenz S, Ruprecht K, et al. Analysis of anti-ganglioside antibodies by a line immunoassay in patients with chronic-inflammatory demyelinating polyneuropathies (CIDP). Clin Chem Lab Med 2018;56(6):919-26. PMID 29329103
- 21
- Kornberg AJ, Pestronk A. Antibody-associated polyneuropathy syndromes: principles and treatment. Semin Neurol 2003;23(2):181-9. PMID 12894383
- 22
- Latov N. Pathogenesis and therapy of neuropathies associated with monoclonal gammopathies. Ann Neurol 1995;37:S32-42. PMID 8968215
- 23
- Lee KP, Abdul Halim S, Sapiai NA. A Severe pharyngeal-sensory-ataxic variant of Guillain-Barré syndrome with transient cardiac dysfunction and a positive anti-sulfatide IgM. Cureus 2022;14(9):e29261. PMID 36277590
- 24
- Li Y, Tang M, Yu L, et al. Anti-ganglioside antibody positive neuromyelitis optica spectrum disorders with peripheral neuropathy: a case report. BMC Neurol 2023;23(1):189. PMID 37173637
- 25
- Lopate G, Parks BJ, Goldstein JM, Yee WC, Friesenhahn GM, Pestronk A. Polyneuropathies associated with high titre antisulfatide antibodies: Characteristics of patients with and without serum monoclonal proteins. J Neurol Neurosurg Psychiatry 1997a;62:581-5. PMID 9219742
- 26
- Lopate G, Pestronk A, Evans S, Li L, Clifford D. Anti-sulfatide antibodies in HIV-infected individuals with sensory neuropathy. Neurology 2005;64(9):1632-4. PMID 15883332
- 27
- Lopate G, Pestronk A, Kornberg AJ, Yue J, Choksi R. IgM anti-sulfatide autoantibodies: patterns of binding to cerebellum, dorsal root ganglion and peripheral nerve. J Neurol Sci 1997b;151:189-93. PMID 9349675
- 28
- Mata S, Ambrosini S, Saccomanno D, et al. Anti-MAG IgM: differences in antibody tests and correlation with clinical findings. Neurol Sci 2020;41(2):365-72. PMID 31654362
- 29
- Mata S, Torricelli S, Barilaro A, et al. Polyneuropathy and monoclonal gammopathy of undetermined significance (MGUS); update of a clinical experience. J Neurol Sci 2021;423:117335. PMID 33647732
- 30
- Meehan GR, McGonigal R, Cunningham ME, et al. Differential binding patterns of anti-sulfatide antibodies to glial membranes. J Neuroimmunol 2018;323:28-35. PMID 30196830
- 31
- Melendez-Vasquez C, Redford J, Choudhary PP, et al. Immunological investigation of chronic inflammatory demyelinating polyradiculoneuropathy. J Neuroimmunol 1997;73:124-34. PMID 9058768
- 32
- Nardelli E, Bassi A, Mazzi G, Anzini P, Rizzuto N. Systemic passive transfer studies using IgM monoclonal antibodies to sulfatide. J Neuroimmunol 1995;63:29-37. PMID 8557822
- 33
- Nemni R, Fazio R, Quattrini A, Lorenzetti I, Mamoli D, Canal N. Antibodies to sulfatide and chondroitin sulfate C in patients with chronic sensory neuropathy. J Neuroimmunol 1993;43:79-86. PMID 8384638
- 34
- Nobile-Orazio E, Manfredini E, Carpo M. et al. Frequency and clinical correlates of anti-neural IgM antibodies in neuropathy associated with IgM monoclonal gammopathy. Ann Neurol 1994;36:416-24. PMID 8080249
- 35
- Pestronk A. Autoantibodies and immune polyneuropathies. In: Katirji B, Kaminski HJ, Preston DC, Ruff RL, Shapiro BE, editors. Neuromuscular disorders in clinical practice. Woburn: Butterworth-Heinemann, 2002:48-63.
- 36
- Pestronk A, Choksi R, Bieser K, et al. GALOP syndrome: a treatable autoimmune gait disorder with late-age onset. Ann Neurol 1993;34:268-9.
- 37
- Pestronk A, Choksi R, Bieser K, et al. Treatable gait disorder and polyneuropathy associated with high titer serum IgM binding to antigens that copurify with myelin-associated glycoprotein. Muscle Nerve 1994;17:1293-300. PMID 7523945
- 38
- Pestronk A, Li F, Griffin J, et al. Polyneuropathy syndromes associated with serum antibodies to sulfatide and myelin-associated glycoprotein. Neurology 1991;41:357-62. PMID 1706491
- 39
- Petratos S, Turnbull VJ, Papadopoulos R, Ayers M, Gonzales MF. Peripheral nerve binding pattern of anti-sulfatide antibodies in HIV-infected individuals. NeuroReport 1999a;10:1659-64. PMID 10501553
- 40
- Petratos S, Turnbull VJ, Papadopoulos R, Ayers M, Gonzales MF. High titer anti-sulfatide antibodies in HIV-infected individuals. NeuroReport 1999b;10:2557-62. PMID 10574369
- 41
- Petratos S, Turnbull VJ, Papadopoulos R, Ayers M, Gonzales MF. High-titre IgM anti-sulfatide antibodies in individuals with IgM paraproteinemia and associated peripheral neuropathy. Immunol Cell Biol 2000;78(2):124-32. PMID 10762412
- 42
- Quattrini A, Corbo M, Dhaliwal SK, et al. Anti-sulfatide antibodies in neurological disease: binding to rat dorsal root ganglia neurons. J Neurol Sci 1992;112:152-9. PMID 1469427
- 43
- Roggenbuck D, Delmont E, Reinhold D, Schierack P, Conrad K, Boucraut J. Autoimmune peripheral neuropathies and contribution of antiganglioside/sulphatide autoantibody testing. Mediterr J Rheumatol 2020;31(1):10-18. PMID 32411930
- 44
- Ryberg B. Multiple specificities of antibrain antibodies in multiple sclerosis and chronic myelopathy. J Neurol Sci 1978;38:357-82. PMID 731263
- 45
- Saccomanno D, Tomba C, Magri F, et al. Anti-sulfatide reactivity in patients with celiac disease. Scand J Gastroenterol 2017;52(4):409-13. PMID 27908207
- 46
- Shigeta H, Yamaguchi M, Nakano K, et al. Serum antibodies against sulfatide and phospholipid in NIDDM patients with diabetic neuropathy. Diabetes Care 1997;20:1896-9. PMID 9405914
- 47
- Toda G, Ikeda Y, Kashiwagi M, Iwamori M, Oka H. Hepatocyte plasma membrane glycosphingolipid reactive with sera from patients with autoimmune chronic active hepatitis; its identification as sulfatide. Hepatology 1990;12:664-70. PMID 2210670
- 48
- Van den Berg LH. Neuropathies associated with anti-sulfatide and other glycoconjugate antibodies. In: Latov N, Wokke JH, Kelly Jr JJ, editors. Immunological and infectious diseases of the peripheral nerves. Cambridge: Cambridge University Press, 1998:201-7.
- 49
- Van den Berg LH, Lankamp CL, de Jager AE, et al. Anti-sulphatide antibodies in peripheral neuropathy. J Neurol Neurosurg Psychiatry 1993;56:1164-8. PMID 8229027
- 50
- van Vliet HH, Kappers-Klune MC, van der Hel JW, Abels J. Antibodies against glycosphingolipids in sera of patients with idiopathic thrombocytopenic purpura. Br J Haematol 1987;67(1):103-8. PMID 3663515
- 51
- Wolfe GI, Nations SP. Guide to autoantibody testing in peripheral neuropathies. Neurologist 2001;7:195-207.
- 52
- Zhao M, Gu Y, Zhao J, Li N. AntiGQ1b antibody positive with MFS/GBS overlapped syndrome with diplopia and hemiplegia onset: case report and retrospective analysis. Medicine (Baltimore) 2022;101(37):e30584. PMID 36123885
Contributors
All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.
Author
-
Louis H Weimer MD
Dr. Weimer of Columbia University has no relevant financial relationships to disclose.
See Profile
Former Authors
- Ron A Dabby MD and Norman Latov MD PhD (original authors), Jaya R Trivedi MD, Gil I Wolfe MD
Patient Profile
- Age range of presentation
-
- 19 to 65+ years
- Sex preponderance
-
- male=female
- Heredity
-
- none
- Population groups selectively affected
-
- none selectively affected
- Occupation groups selectively affected
-
- none selectively affected
ICD & OMIM codes
- ICD-9
-
- Unspecified idiopathic peripheral neuropathy: 356.9
- ICD-10
-
- Hereditary and idiopathic neuropathy, unspecified: G60.9
This is an article preview.
Start a Free Account
to access the full version.
-
Nearly 3,000 illustrations, including video clips of neurologic disorders.
-
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
-
Full spectrum of neurology in 1,200 comprehensive articles.
-
Listen to MedLink on the go with Audio versions of each article.
Questions or Comment?
MedLink®, LLC
3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122
Toll Free (U.S. + Canada): 800-452-2400
US Number: +1-619-640-4660
Support: service@medlink.com
Editor: editor@medlink.com
ISSN: 2831-9125
Also in This Category
-
-
Peripheral Neuropathies
Clinical evaluation of peripheral neuropathies
Oct. 24, 2024
-
General Neurology
Hypothyroidism
Sep. 27, 2024
-
Peripheral Neuropathies
Monoclonal gammopathy of neurologic significance
Sep. 10, 2024
-
Neuroimmunology
Chronic inflammatory demyelinating polyradiculoneuropathy
Sep. 07, 2024
-
Peripheral Neuropathies
Amyotrophic lateral sclerosis
Sep. 04, 2024
-
Peripheral Neuropathies
Amiodarone neuropathy
Sep. 04, 2024
-
Neuroimmunology
Autoimmune autonomic neuropathy
Aug. 31, 2024